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Background: Hydromethylthionine is a potent inhibitor of pathological aggregation of tau and TDP-43 proteins.28
Objective: To compare hydromethylthionine treatment effects at two doses and to determine how drug exposure is related
to treatment response in bvFTD.
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Methods: We undertook a 52-week Phase III study in 220 bvFTD patients randomized to compare hydromethylthionine at
200 mg/day and 8 mg/day (intended as a control). The principal outcomes were change on the Addenbrookes Cognitive Exam-
ination – Revised (ACE-R), the Functional Activities Questionnaire (FAQ), and whole brain volume. Secondary outcomes
included Modified Clinical Global Impression of Change (Modified-CGIC). A population pharmacokinetic exposure-response
analysis was undertaken in 176 of the patients with available blood samples and outcome data using a discriminatory plasma
assay for the parent drug.
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Results: There were no significant differences between the two doses as randomized. There were steep concentration-
response relationships for plasma levels in the range 0.3–0.6 ng/ml at the 8 mg/day dose on clinical and MRI outcomes. There
were significant exposure-dependent differences at 8 mg/day for FAQ, Modified-CGIC, and whole brain atrophy comparing
patients with plasma levels greater than 0.346 ng/ml with having minimal drug exposure. The exposure-response is biphasic
with worse outcomes at the high concentrations produced by 200 mg/day.
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Conclusions: Hydromethylthionine has a similar concentration-response profile for effects on clinical decline and brain
atrophy at the 8 mg/day dose in bvFTD as recently reported in AD. Treatment responses in bvFTD are predicted to be
maximal at doses in the range 20–60 mg/day. A confirmatory placebo-controlled trial is now planned.
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INTRODUCTION31
Behavioral variant frontotemporal dementia32
(bvFTD) is a clinical syndrome characterized by33
progressive deterioration of personality, social34
comportment, and cognition [1]. Although a rare35
disorder, bvFTD is the second most common36
cause of dementia under age 65; there are also37
a significant number of cases in older people [2,38
3]. The diagnosis of bvFTD is primarily clinical,39
with insidious onset and progressive deterioration,40
the core symptoms being disinhibition, apathy,41
lack of empathy, compulsions, hyperorality, and42
impairment of executive function. There are also43
patients who exhibit similar symptoms, but who do44
not suffer from a neurodegenerative condition [4,45
5]. This phenocopy is characterized by preservation46
of functional ability [6], absence of a genetic47
abnormality [3], and normal imaging [5]. Patients48
with bvFTD decline significantly more rapidly on49
cognitive and functional measures than patients50
with AD [7], with mean survival from symptom51
onset approximately 8 years [8]. For a given level of52
severity, prevalence of significant burden in carers is53
much higher in bvFTD compared with AD [9], and54
patients with neuropathologically confirmed bvFTD55
have a significantly higher prevalence of criminal56
and socially inappropriate behavior compared with57
AD [10]. Because the typical age of onset is earlier58
than for AD [11, 12], the condition has a direct59
impact on working life and on household income. At60
2016 US costs, bvFTD was found to reduce income61
from $75,000–$99,000 before diagnosis to $50,000.62
There are no treatments licensed for any form 63
of FTD. There is no reliable evidence of benefit 64
for acetylcholinesterase inhibitors [13, 14] and some 65
suggestion that they may make FTD symptoms worse 66
[15, 16]. Memantine is better tolerated but is also 67
ineffective [17, 18]. There have been numerous small 68
studies of other drugs targeting the behavioral symp- 69
toms, with some evidence of a small beneficial effect 70
of trazadone on Neuropsychiatric Inventory (NPI) 71
score [19]. However, the NPI is unsuitable as an out- 72
come measure because the increasing passivity that 73
accompanies disease progression is scored as a better 74
outcome [20]. 75
bvFTD and AD are both members of a class of pro- 76
gressive neurodegenerative disorders characterized 77
by pathological aggregation and prion-like spread of 78
otherwise normal proteins [21]. The largest consecu- 79
tive bvFTD autopsy study published to date showed 80
there is high confidence of a clinical diagnosis of 81
bvFTD; characteristic pathology is present in 94% 82
of cases, with 84% having pathological aggregation 83
of tau protein (27%) or transactive response DNA 84
binding protein 43 (TDP-43; 57%) [22]. There is 85
increasing recognition of the importance of tau aggre- 86
gation pathology as a substrate of clinical dementia 87
and as a target for therapy in AD [23], and by 88
implication in prion-like neurodegenerative disorders 89
involving other proteins such as TDP-43. 90
The most advanced late-stage program target- 91
ing pathological protein aggregation currently in 92
development is based on leuco-methylthioninium 93
bis(hydromethanesulphonate) (LMTM) [24]. LMTM 94
has recently been assigned the International 95
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Nonproprietary Name (INN) ‘hydromethylthionine’,96
recognizing it as chemically and pharmacologi-97
cally distinct from methylthioninium chloride (MTC,98
methylene blue). The methylthioninium (MT) moi-99
ety can exist in oxidized (MT+) and reduced (LMT)100
forms. LMTM is a stabilized salt of LMT which has101
better brain uptake and tolerability than the oxidized102
MT+ form [24, 25]. We have retained the LMTM103
abbreviation in contexts that require technical dis-104
cussion of the distinctive properties of LMT, but105
otherwise we now use the INN more generally. We106
have reported recently that LMT rather than MT+ is107
the active species blocking tau aggregation in vitro108
and that it acts at a tau:LMT molar ratio of 1 : 0.1109
[26]. Its site of action is within the proteolytically110
stable core tau unit of the tau aggregates found in111
both bvFTD and AD [27–29]. LMT blocks aggre-112
gation of the core tau unit in cell-based assays [24,113
26] and reduces tau aggregation pathology and asso-114
ciated behavioral deficits in a tau transgenic mouse115
model of bvFTD at clinically relevant doses [30].116
There was increased clearance of pathological tau117
via enhancement of autophagy at the 10–20 nM con-118
centration range in a mouse model of bvFTD [31]119
and reversal of resistance of filamentous tau to pro-120
teases [24, 32]. The MT moiety inhibits aggregation121
of TDP-43 in cell models with an EC50 of 0.05M122
[24], although not in a mouse overexpression model123
at a dose unlikely to have been sufficient for MTC124
activity [33].125
The MT moiety has a range of other properties126
that affect cellular metabolism. It has been known127
for some time that it enhances mitochondrial activ-128
ity at low concentrations (10–100 nM) [34, 35] by129
acting as a supplementary electron carrier in the elec-130
tron transfer chain. This has been confirmed recently131
in an AD-like tau transgenic mouse model in which132
hydromethylthionine was found to increase Complex133
IV activity in the brain at clinically relevant doses134
[36]. It is able to induce mitochondrial biogenesis and135
to activate Nrf2-mediated oxidative stress response136
elements in vivo [37]. Other potentially beneficial137
activities include neuroprotective effects in the brain138
by inhibiting microglial activation and increasing139
autophagy [38]. Therefore, in addition to its actions140
on tau and TDP-43 aggregation, the MT moiety has141
complementary actions which address many of the142
pathways currently advocated as having potential for143
the treatment of neurodegenerative diseases [39–41].144
We have previously reported the results of two145
Phase III trials using hydromethylthionine in AD146
[42, 43]. Both trials were designed as dose com-147
parison studies, comparing doses in the range 148
150–250 mg/day with a low dose (8 mg/day) that was 149
intended as a control to mask the urinary discoloration 150
that occurs variably when urine from patients taking 151
any form of MT is exposed to air [44]. The expec- 152
tation was that this low dose would have no effect 153
on brain structure or function, an expectation based 154
on the results of an earlier placebo-controlled dose- 155
finding Phase II trial using MTC which identified 156
138 mg/day as the minimum effective dose in AD 157
[45], and early comparative Phase I pharmacokinetic 158
studies showing similar plasma levels of total MT 159
measured after acid extraction of samples [46]. How- 160
ever, we have found that this assay is dominated by 161
an acid-labile inactive conjugate in plasma which is 162
not distinguished from the active parent form of the 163
drug following acid extraction. 164
We have developed a sensitive assay which can 165
measure parent drug levels in plasma and which has 166
been found to be reliable and accurate in preclinical 167
and Phase I studies. Using this assay in a population 168
pharmacokinetic (PK) study in 1,162 patients partici- 169
pating in the AD trials, we recently reported [47] that 170
there is a steep concentration-response relationship 171
on all clinical and brain magnetic resonance imaging 172
(MRI) outcomes in patients receiving the 8 mg/day 173
dose. Hydromethylthionine therefore has pharmaco- 174
logical activity on brain structure and function in the 175
majority of patients at this dose. We also found that 176
there is a predicted plateau in response at theoretical 177
doses above 16 mg/day, consistent with the lack of 178
dose-response at much higher doses in AD [47]. 179
The design of the present Phase III study in bvFTD 180
(TRx-237-007) was based on the same underlying 181
premise as the AD trials, comparing a high dose of 182
hydromethylthionine (200 mg/day given in divided 183
doses twice daily) with a low dose (8 mg/day given 184
in divided doses twice daily). We now report that, as in 185
AD, there was no overall difference on any endpoint 186
between these two doses in bvFTD. We also report 187
the results of the embedded population PK analysis of 188
clinical and MRI biomarker outcomes similar to that 189
recently reported in AD [47], to determine how drug 190
exposure is related to treatment response in bvFTD. 191
MATERIALS AND METHODS 192
Study design and participants, randomization 193
and masking, and outcomes 194
The study was designed as a 52-week Phase III, 195
randomized, controlled, double-blind, parallel-group 196
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trial conducted between May 2013 and February197
2016 at 70 sites in Canada, United States, Aus-198
tralia, Asia, and Europe. Eligible patients had to199
be younger than 80 years of age with a diagno-200
sis of bvFTD according to criteria revised by the201
International bvFTD Criteria Consortium [1, 48],202
with Mini-Mental Status Examination (MMSE) score203
greater than or equal to 20 at screening. In order to204
limit inclusion of bvFTD phenocopy cases, there was205
an additional requirement that patients had to meet206
the criterion of having definite brain atrophy in frontal207
and/or temporal lobes scoring 2 or more on a scale208
previously developed by Kipps et al. [49]. Concomi-209
tant use of acetylcholinesterase inhibitors (AChEIs)210
or memantine (or both) was permitted provided this211
was at a stable dose for at least 18 weeks before212
randomization to minimize any potential early symp-213
tomatic effects of these treatments. Concomitant use214
of antidepressant, antipsychotic (except clozapine or215
olanzapine), and sedative medications was also per-216
mitted at stable doses where clinically feasible. Each217
patient had one or more study partners participate218
with them in the trial as informants. Patients were219
excluded from the study if they had a significant CNS220
disorder other than bvFTD. A detailed list of inclu-221
sion and exclusion criteria is in the protocol provided222
in the Supplementary Material.223
Patients were randomly assigned to receive224
hydromethylthionine 100 mg twice a day or225
hydromethylthionine 4 mg twice a day (n = 220). The226
randomization was stratified according to geograph-227
ical region (three levels: North America, Europe,228
Asia/Australia). The randomization file and investi-229
gational medicinal product kit list were unavailable230
to personnel involved in conducting the study prior231
to final analysis after database lock. Study partici-232
pants, their informant(s), and all assessors remained233
masked to treatment assignment throughout the study,234
and safety assessors were not permitted to be involved235
in efficacy assessments.236
The two doses were provided in identical blis-237
ter packages as visually identical oral tablets to238
be taken for up to 52 weeks. The primary out-239
come was the Addenbrookes Cognitive Examination240
– Revised (ACE-R) [50]. The Functional Activ-241
ities Questionnaire (FAQ) [51] and reduction in242
progression of whole brain atrophy were alterna-243
tive co-primary outcomes. Other outcomes included:244
Modified Alzheimer’s Disease Cooperative Study –245
Clinical Global Impression of Change (Modified-246
CGIC) [20] determined by a third independent rater;247
Frontotemporal Dementia Rating Scale (FRS) [52];248
MMSE (from MMSE items incorporated into ACE- 249
R); Addenbrookes Cognitive Examination – III (a 250
revised version of ACE-R which excludes MMSE 251
items subject to copyright restrictions [53]); change in 252
brain volume measured by MRI in frontal and tempo- 253
ral lobes (FTV) and lateral ventricles (LVV); and the 254
effect of hydromethylthionine in patients with known 255
genetic mutations associated with bvFTD. Blood was 256
collected prospectively for the purpose of population 257
PK analyses. 258
MRI scans were obtained at screening and weeks 259
16, 32, and 52. The acquisition protocol was standard- 260
ized across sites and all data were centrally collected, 261
quality-controlled, and analyzed by the imaging 262
core laboratory (Bioclinica). MRI data included a 263
3D sagittal T1-weighted sequence (using parameters 264
compatible with the ADNI protocol) which was used 265
for all volumetric analyses. For data passing quality- 266
control, baseline volume was automatically assessed 267
using FreeSurfer v5.3, while volume changes were 268
assessed using Boundary Shift Integral (whole brain, 269
lateral ventricles) [54] and Tensor-Based Morphom- 270
etry (frontal and temporal lobes) [55]. 271
Patients were monitored throughout the study for 272
adverse events, including use of clinical laboratory 273
tests (including measurement of methaemoglobin 274
by pulse CO-oximetry), physical and neurological 275
examinations, and 12-lead electrocardiograms (ECG) 276
at all clinic visits (screening, baseline, and weeks 2, 277
16, 32, 52, and 56). The Unified Parkinson’s Disease 278
Rating Scale Part III (UPDRS) [56] was included as 279
a motor safety outcome measure requested by a regu- 280
latory agency, as was the Columbia-Suicide Severity 281
Rating Scale (C-SSRS) [57], which were assessed 282
at all visits. Patients were also systematically moni- 283
tored for potential serotonin syndrome using a rating 284
scale derived from four published diagnostic criteria 285
[58], because of a theoretical potential for serotonin 286
syndrome [59]. By protocol, amyloid related imaging 287
abnormalities (ARIA), serotonin toxicity, and suici- 288
dality were to be reported as serious adverse events 289
for expedited reporting. 290
Statistical analysis 291
The primary analyses were conducted in the 292
Modified Intent-to-Treat (MITT) population (all ran- 293
domized patients who took at least one dose of study 294
drug and had both a Baseline and at least one post- 295
Baseline efficacy assessment; n = 214). The MRI 296
imaging population comprised all MITT population 297
patients with a Screening/Baseline and at least one 298
Un
co
rre
cte
d A
uth
or
 P
ro
of
H. Shiells et al. / Hydromethylthionine Reduces bvFTD Clinical Decline and Brain Atrophy 5
valid post-baseline volumetric assessment (n = 209).299
The primary analyses were specified as a mixed300
model, repeated-measures analysis with an unstruc-301
tured covariance matrix and no imputation for302
missing data. The model included visit (three lev-303
els corresponding to assessments at weeks 16, 32,304
and 52), treatment group (two levels, 4 mg or 100 mg305
twice a day), a visit by treatment group interaction306
term, use of AD-labelled medications (two levels,307
using or not using), geographic region (three levels:308
North America, Asia/Australia, Europe), and base-309
line value of the variable analyzed. The individual310
comparisons were implemented through contrasts.311
The Bonferroni-Holm correction was used to take312
account of multiplicity arising from alternative co-313
primary outcomes (FAQ and whole brain atrophy).314
We used the same method for all secondary analyses315
in predefined gated sequences such that no further316
adjustment of alpha (0.05) was needed.317
A sensitivity analysis was conducted to compare318
baseline MRI scans with those available from the319
parallel study in mild AD (TRx-237-005) [42] using320
the Statistical Parametric Mapping (SPM12) software321
package (http://www.fil.ion.ucl.ac.uk/spm/)) in anal-322
yses controlled for age, sex, and total intracranial323
volume.324
Safety analyses were based on the Safety Popu-325
lation comprising 218 patients who received at least326
one dose of study drug, with summaries presented327
according to dose.328
Data analyses specified in the Statistical Analysis329
Plan were undertaken independently of the fun-330
der by SynteractHCR (Carlsbad, CA, USA) using331
SAS 9.4 (Enterprise Guide v7.1). The results were332
verified and additional exploratory analyses were333
provided by two of the co-authors (HS, BOS) using R334
version 3.3.0 (2016-05-03). Additional voxel-based335
morphometric analyses (VBM) were provided by VV,336
TA, and RTS using the SPM12 software package.337
This trial is registered at http://www.clinicaltrials.gov338
(NCT01626378) and the European Union Clinical339
Trials Registry (EudraCT 2011-005529-34).340
Population PK analysis341
Blood samples for assessment of parent MT, N-342
desmethyl MT, and total MT (sum of parent MT343
and a labile LMT conjugate), were collected from344
each patient on the first treatment visit (two sam-345
ples: pre-dose and approximately 3.5 h after the dose)346
and at each subsequent on-treatment visit. The pro-347
tocol specified that PK plasma sampling was to348
be conducted only at sites with adequate facilities 349
(i.e., a refrigerated centrifuge and adequate capabil- 350
ity to freeze samples reliably). Blinded analyses were 351
conducted at the University of Aberdeen GLP Test 352
Facility. MT levels in plasma were measured using 353
liquid chromatography-tandem mass spectrometry 354
assay. The method was validated for use in the Phase 355
III studies over the range 0.2 to 10 ng/ml. Extrap- 356
olated MT concentrations were available below the 357
lower limit of quantitation (but above the lower 358
limit of detection) in approximately 35% of the 359
Day 1 patients randomized to the 8 mg/day dose. 360
Model development and estimation of steady state 361
maximum plasma concentration (Cmax,ss) were deter- 362
mined independently by the Institute of Clinical 363
Pharmacodynamics (ICPD, NY, USA). Cmax,ss esti- 364
mates using a model validated in Phase I studies 365
were based on in-clinic plasma concentration data 366
obtained on Day 1 when the dose-sampling interval 367
was accurately recorded. The percentage of patients 368
with Day 1 exposure levels below the lower calibra- 369
tion limit of the assay was used to define a proxy 370
for placebo in post-hoc binary statistical compar- 371
isons of patients with low and high exposure to 372
the drug with a view to informing the design of 373
a future placebo-controlled trial. Change in ACE- 374
R, ACE-III, FAQ, MMSE, Modified-CGIC, FRS, 375
whole brain volume (WBV), lateral ventricular vol- 376
ume (LVV), and frontotemporal volume (FTV), as 377
well as UPDRS Part III, were expressed as a func- 378
tion of Cmax,ss estimates grouped into four groups 379
described in the results section. Cmax,ss values outside 380
3x the interquartile range were excluded from deter- 381
mination of concentration-response relationships, but 382
were included in inferential statistical analyses. 383
The concentration-response analyses used a 384
Mixed-effect Model Repeat Measurement (MMRM) 385
with per-subject correction and an unstructured 386
covariance matrix according to the following for- 387
mula: 388
Treatment effect∼ plasma-level x visit + plasma- 389
level x co-medication-status + co-medication-status x 390
visit + MMSE-class x visit + sex x visit + age-class x 391
visit + geographical-region + baseline-score 392
The following terms were categorical variables in 393
the models used for concentration-response analy- 394
ses: plasma level (five levels), visit (three levels), 395
co-medication status with AD drugs (two levels), 396
geographical-region (three levels),MMSE-class (two 397
levels, ≤20 and >21), and age-class (two levels, ≤65 398
and ≥66). For the longitudinal analyses, plasma level 399
was described by two levels (above or below thresh- 400
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old). The sex x visit andage x visit terms were included401
because of the significant differences in baseline402
severity between males and females and the likely403
influence of age given that the age range of patients404
in this study was wide (42–79 years). Since sever-405
ity was shown to be a significant parameter in the406
primary ACE-R and FAQ analyses, severity as deter-407
mined by MMSE score was used as a rate term in408
the model as MMSE-class x visit. There were too few409
cases (14) taking LMTM in combination with AD-410
labelled drugs in whom plasma concentration and411
efficacy data were both available to permit separate412
analyses according to co-medication status to be con-413
ducted. Pharmacodynamic analyses were undertaken414
independently by ICPD and were confirmed by HS415
and BOS.416
A further analysis was undertaken (HS, BOS)417
using a modified form of the Hill equation which is418
commonly used in the analysis of pharmacological419
data [60] in order to estimate the minimum and420
maximum plasma concentrations for expected treat-421
ment response over 52 weeks. The Hill equation was422
applied under the assumption of non-cooperativity423
and used imposed zero values where the no-effect424
level was taken as -12 ACE-R units, 8 FAQ units425
or –30 cm3 for whole brain volume at a Cmax,ss426
concentration of 0.29 ng/ml based on visual inspec-427
tion of the data. Use of different limiting values did428
not meaningfully change the results. In addition, a429
linear term was added to permit trends occurring430
at high concentrations to be included in the model.431
For decline in whole brain volume at this dose,432
patients were split further into terciles to permit433
estimation of the maximum limiting concentration434
at which the treatment effect was lost. The mod-435
ified Hill equation was applied to the data in the form:436
437
change in parameter = Emin − (Emax x([C]−438
0.29))/(EC50 + ([C] − 0.29)) + (A x ([C] − 0.29))
439
where Emin and Cmin are the imposed zero values,440
where E in the mean treatment response for any441
given Cmax,ss subgroup; Emax is the maximum442
treatment effect as estimated from a standard Hill443
equation without the additional linear term; EC50 is444
the Cmax,ss at which the treatment effect is 50% of445
the maximum response as estimated from a standard446
Hill equation without the additional linear term;447
A x (Cmax ,ss – Cmin ) is a further linear term in448
which A is estimated by the model to take account449
of the trends seen at high concentrations. In order to450
relate Cmax,ss values to theoretical doses in a future451
trial, a linear model was fitted to the mean plasma 452
concentrations at the 8, 150, 200, and 250 mg/day 453
doses using data from both AD and bvFTD patients: 454
455
estimated dose = 22.22 x (Cmax ,ss – 0.016)
456
where dose is in mg/day and Cmax,ss is in ng/ml units. 457
Role of the funding source 458
The funder of the study (TauRx) took the lead in 459
study design, undertaking the study, data interpreta- 460
tion, and initial drafting of the report. 461
RESULTS 462
Study disposition and population characteristics 463
at baseline 464
The disposition of patients randomized to Study 465
007 is shown in Fig. 1. 466
Of 1,030 patients who were initially thought to be 467
suitable for inclusion in the trial by investigators, 810 468
(78.6%) were found to be ineligible either during pre- 469
liminary assessment prior to screening (661, 64.2%) 470
or at formal screening (149, 14.5%), with only 220 471
(21.4%) enrolled and randomized. Reasons relating 472
to diagnosis (clinical and MRI imaging) and severity 473
accounted for the majority exclusions (309, 30.0%). 474
Only 18 (1.7%) exclusions were due to meeting DSM 475
IV criteria for other psychiatric conditions, whereas 476
71 (6.6%) were due to other neurological disorders 477
and a further 81 (7.9%) were found not to meet cri- 478
teria for probable bvFTD, with the majority of these 479
excluded prior to formal screening. As expected, the 480
majority of medical exclusions (38 from a total of 47 481
[5.8%]) emerged only during formal screening. Oper- 482
ational reasons represented the second largest group 483
of exclusions overall (227, 28.0%), including unwill- 484
ingness to participate (86, 8.3%), inability to comply 485
with study procedures (64, 6.2%), and residence in 486
continuous care facility (26, 2.5%) as the largest cat- 487
egories. Overall, therefore, only 20% of patients that 488
investigators initially thought might be suitable met 489
the criteria for enrolment. 490
The demographic characteristics of the 220 491
patients randomized are summarized in Table 1. 492
Mean age was 63.3 years, ranging from 42 to 79 493
years, with more men (63%) than women (37%). 494
Patients were distributed geographically between 495
Europe (46%), North America (41%), and Aus- 496
tralia/Asia (13%). 497
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Fig. 1. Trial profile.
Table 1
Demographic characteristics of the randomized Intent to Treat Population
Characteristic Hydromethylthionine Hydromethylthionine Total
8 mg/day 200 mg/day
(n = 111) (n = 109)
Age (y)
Mean (SD) 63.1 (7.35) 63.6 (7.52) 63.3 (7.42)
Median (range) 63.0 (43–78) 64.0 (42–79) 63.0 (42–79)
n (%) <60 y 32 (28.8%) 27 (24.8%) 59 (26.8%)
n (%) ≥60 y 79 (71.2%) 82 (75.2%) 161 (73.2%)
Sex n (%)
Male 67 (60.4%) 71 (65.1%) 138 (62.7%)
Female 44 (39.6%) 38 (34.9%) 82 (37.3%)
Race n (%)
American Indian or Alaska Native 4 (3.6%) 4 (3.7%) 8 (3.6%)
Asian 4 (3.6%) 3 (2.8%) 7 (3.2%)
Black or African American 0 1 (0.9%) 1 (0.5%)
White 102 (91.9%) 99 (90.8%) 201 (91.4%)
Other 1 (0.9%) 2 (1.8%) 3 (1.4%)
Patients had been diagnosed with bvFTD for498
almost 2 years on average (median, 1.1 years; rang-499
ing up to 17.6 years). The mean MMSE (SD) at500
baseline was 24.6 (3.1) with an almost equal distri-501
bution of patients with a score of 22–26 (85 patients,502
39%) and greater than 26 (81 patients, 37%). Females503
were more impaired than males on the MMSE scale504
(males 25.4 (3.5), females 22.9 (4.0), p < 0.001) and505
ACE-R (males 72 (16), females 62 (14), p < 0.001)506
scales, although not on the FAQ or FRS scales. Sever-507
ity of frontotemporal atrophy was predominantly508
Kipps stages 2 or 3 (82.3%) with 17.7% [49] at509
Kipps stage 4 (Table 2). Baseline disease charac- 510
teristics were similar in distribution across treatment 511
groups, regions, and centers. Comparative summaries 512
of baseline biological characteristics of patients in 513
the present bvFTD study and the AD study popu- 514
lations reported previously [42, 43] are provided in 515
Supplementary Tables 1–3. 516
Co-medication utilization is summarized in 517
Table 3. Approximately one-fifth of all patients (21% 518
overall) were receiving an AChEI and/or memantine 519
therapy at screening, while almost half (46%) were 520
using medical food or alternative pharmacotherapy. 521
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Table 2
Clinical characteristics of patients at baseline
Characteristic Hydromethylthionine Hydromethylthionine Total
8 mg/day 200 mg/day
(n = 111) (n = 109)
Years since bvFTD diagnosis
N 107 106 213
Mean (SD) 1.9 (2.4) 1.9 (2.4) 1.9 (2.4)
Median (range) 0.9 (0.0–14.9) 1.1 (0.0–17.6) 1.1 (0.0–17.6)
MMSE score
Mean (SD) 24.6 (3.1) 24.7 (3.0) 24.6 (3.1)
≤21 28 (25.2%) 26 (23.9%) 54 (24.5%)
22–26 46 (41.4%) 39 (35.8%) 85 (38.6%)
>26 37 (33.3%) 44 (40.4%) 81 (36.8%)
Kipps stage, n (%)
2 38 (34.2%) 42 (38.5%) 80 (36.4%)
3 55 (49.5%) 46 (42.2%) 101 (45.9%)
4 18 (16.2%) 21 (19.3%) 39 (17.7%)
Table 3
Co-medication status of patients in study
Characteristic Hydromethylthionine Hydromethylthionine Total
8 mg/day 200 mg/day
(n = 111) (n = 109)
Use of AChEI/memantine (Concomitant medication) n (%)
AChEI and/or memantine 25 (22.5%) 20 (18.3%) 45 (20.5%)
Both AChEI and memantine 7 (6.3%) 3 (2.8%) 10 (4.5%)
AChEI only 10 (9.0%) 7 (6.4%) 17 (7.7%)
Memantine only 8 (7.2%) 10 (9.2%) 18 (8.2%)
Use of Medical Food or Alternative Pharmacotherapy for Dementia n (%)
Yes 54 (48.6%) 49 (45.0%) 103 (46.8%)
No 57 (51.4%) 60 (55.0%) 117 (53.2%)
Use of Selective Serotonin Reuptake Inhibitor (SSRI) n (%)
Yes 30 (27.0%) 33 (30.3%) 63 (28.6%)
No 81 (73.0%) 76 (69.7%) 157 (71.4%)
Use of Drugs of Serotonergic Potential n (%)
Yes 49 (44.1%) 62 (56.9%) 111 (50.5%)
No 62 (55.9%) 47 (43.1%) 109 (49.5%)
Fig. 2. Voxel-based morphometric comparison showing regions
of greater atrophy (yellow) in patients with bvFTD compared to
AD patients with mild AD (n = 713), from study TRx-237-005,
controlled for age, sex, and total intracranial volume of each indi-
vidual. Blue color indicates greater atrophy in AD patients. Data
are displayed at a significance threshold corrected for family-wise
error at the whole brain level at p < 0.05.
Antidepressant serotonergic reuptake inhibitors were 522
used by 29%, and drugs with potential serotonergic 523
activity were taken by 50%. 524
Validation of diagnosis and genetic mutations 525
Since patients in this study were recruited from 70 526
trial sites in 13 countries (not necessarily from FTD 527
specialist centers), we sought to determine the extent 528
to which patients meeting consensus clinical criteria 529
[1] and the further requirement for evidence of defi- 530
nite frontal and/or temporal lobe atrophy on MRI scan 531
[49] were distinct from mild AD. This was examined 532
by using VBM to compare the distribution of brain 533
atrophy in patients in this study with those enrolled in 534
a parallel study of mild AD (TRx-237-005) in which 535
similar MRI procedures were used. This comparison 536
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is shown in Fig. 2. bvFTD patients in this study had537
significantly more atrophy in frontal cortex and ante-538
rior temporal cortex, and significantly less atrophy539
in hippocampus, middle temporal gyrus, cuneus, and540
insula. We have also reported recently that bvFTD541
patients in this study had significantly more atrophy542
in frontal cortex than the other lobes. This contrasts543
with the AD group, which showed more distributed544
patterns of atrophy and with more atrophy in tempo-545
ral, parietal, and occipital lobes than the bvFTD group546
[61]. The MRI differentiation between bvFTD and547
AD patients is consistent with the high degree of con-548
fidence of a clinical diagnosis of bvFTD previously549
reported in a clinicopathological study [22].550
Of 159 cases analyzed genetically, seven were551
found to have mutations in coding regions for either552
tau (6, 3.8%) or TDP-43 (1). This is similar to the553
frequency previously reported for bvFTD patients554
having tau mutations (3%) [22]. For the one case with555
a TDP-43 mutation, the mutation was I383V. There556
were four cases with a P301L mutation in the tau cod-557
ing region, one with G272V, and one with R406W.558
Treatment effects were not analyzed separately in559
these cases.560
Prespecified efficacy analyses561
There were no significant differences on any of the562
primary or secondary outcomes at 52 weeks between563
patients receiving hydromethylthionine 200 mg/day 564
and those receiving 8 mg/day as randomized and as 565
prespecified in the Statistical Analysis Plan. These 566
results are shown in Table 4. 567
Analyses based on population PK data 568
Data for plasma concentration and time from tak- 569
ing the first dose were available for 172 patients out 570
of 220. Patients receiving hydromethylthionine at a 571
dose of 8 mg/day were split into four groups based on 572
Cmax,ss to provide an independent biological classi- 573
fication according to drug exposure at this dose. The 574
plasma concentration ranges used for this purpose 575
are as indicated in Table 5. The cut-off that defined 576
the upper limit of the lowest 35% group (correspond- 577
ing to the percentage of patients with plasma levels 578
below the validated limit of quantitation on Day 1; 32 579
patients) was 0.346 ng/ml. The remainder with Day 1 580
plasma levels within the validated calibration range of 581
the assay were distributed into terciles having approx- 582
imately 20 patients (22%) each. Small changes in the 583
group boundaries did not meaningfully change the 584
results. As expected, plasma levels in the 81 patients 585
receiving the 200 mg/day dose were 16-fold higher 586
than the highest level seen at 8 mg/day. 587
Concentration-response relationships are shown 588
(Fig. 3) for change in ACE-R, FAQ, WBV, and 589
FTV over 52 weeks for all patients in whom data 590
Table 4
Modeled difference in change from baseline for the respective endpoints comparing patients receiving hydromethylthionine 8 mg/day and
200 mg/day on primary and secondary outcomes. (UPDRS, although a safety outcome, is also included.)
Decline±SEM Difference±SEM CI p
for LMTM 8 mg/day from LMTM 8 mg/day
group (n = 110) for 200 mg/day (n = 104)
ACE-R –9.98 ± 1.39 –0.49 ± 2.10 –4.64, 3.66 0.8170
FAQ 5.51 ± 0.55 –0.39 ± 0.84 –2.05, 1.26 0.6410
WBV (cm3) –21.64 ± 1.56 –1.35 ± 2.32 –5.94, 3.23 0.5614
MMSE –3.41 ± 0.53 –0.12 ± 0.80 –1.69, 1.42 0.8836
CGIC –1.05 ± 0.11 –0.04 ± 0.16 –0.35, 0.28 0.8252
FRS –0.1240 ± 0.0136 0.0075 ± 0.0206 –0.0332, 0.0482 0.7176
ACE-III –10.70 ± 1.55 0.44 ± 2.27 –4.05, 4.93 0.8469
UPDRS – part III 3.90 ± 1.06 –1.40 ± 1.61 –4.59, 1.78 0.3850
Table 5
Plasma-modeled parent MT Cmax,ss for hydromethylthionine groups
Dose groups Cmax,ss (ng/ml)
n (%) Mean (SD) Range
8 mg/day
8 mg/day – Group 1 32 (35%) 0.321 (0.0198) 0.281–0.346
8 mg/day – Group 2 20 (22%) 0.355 (0.0082) 0.346–0.372
8 mg/day – Group 3 19 (21%) 0.387 (0.0121) 0.373–0.409
8 mg/day – Group 4 20 (22%) 0.470 (0.0537) 0.413–0.583
200 mg/day 80 9.040 (1.6259) 6.800–14.235
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Fig. 3. Model-derived least square mean and standard error estimates of change of 52 weeks for clinical (a, b) and MRI volumetric endpoints
(c, d) according to plasma concentration groups (8 mg/day) or dose (200 mg/day).
Table 6
Binary pharmacological activity analysis based on a plasma parent MT threshold of 0.346 ng/ml to define a proxy for placebo; modelled
difference in change from baseline for the respective endpoints
All patients Patients receiving
hydromethylthionine 8 mg/day
Decline ± Difference ± CI p Nlow Nhigh Difference ± CI p Nlow Nhigh
SEM for Cmax,ss SEM for Cmax,ss SEM for Cmax,ss
≤ 0.346 ng/ml > 0.346 ng/ml > 0.346 ng/ml
ACE-R –11.33 ± 2.09 1.37 ± 2.60 –3.73, 6.47 0.5973 30 130 5.06 ± 2.62 –0.08, 10.21 0.0536 30 60
FAQ 7.13 ± 1.06 –2.98 ± 1.10 –5.15, –0.82 0.0069 30 129 –3.27 ± 1.32 –5.85, –0.69 0.0131 30 60
WBV (cm3) –27.72 ± 2.73 9.05 ± 3.06 3.06, 15.04 0.0031 28 115 11.67 ± 3.41 5.00, 18.36 0.0006 28 52
LVV (cm3) 9.13 ± 0.82 –3.41±–0.95 –5.27, –1.55 0.0003 28 107 –4.12 ± 1.06 –6.19, –2.05 <0.0001 28 46
FTV (cm3) –2.47 ± 0.22 0.73 ± 0.24 0.26, 1.19 0.0023 28 115 0.72 ± 0.27 0.19, 1.26 0.0076 28 52
FRS –0.14 ± 0.03 0.04 ± 0.03 –0.02, 0.10 0.1527 30 130 0.04 ± 0.03 –0.03, 0.10 0.2519 30 60
CGIC –1.34 ± 0.20 0.42 ± 0.22 –0.02, 0.85 0.0034 30 130 0.64 ± 0.27 0.12, 1.17 0.0157 30 60
MMSE –2.95 ± 0.93 –0.43 ± 1.05 –2.48, 1.62 0.6788 30 130 0.41 ± 1.04 –1.64, 2.45 0.6974 29 58
ACE-III –9.47 ± 2.40 1.27 ± 2.73 –4.08, 6.61 0.6418 26 122 4.36 ± 2.94 –1.40, 10.13 0.1380 29 58
UPDRS part III 5.71 ± 1.85 –3.27 ± 2.09 –7.37, 0.81 0.1163 29 123 –4.31 ± 2.69 –9.58, 0.95 0.0711 31 62
were available for estimated Cmax,ss of parent MT in591
plasma.592
As can be seen, there are steep concentration-593
response relationships for plasma levels in the range594
0.3–0.6 ng/ml at the 8 mg/day dose on clinical and595
MRI outcomes. The patients with plasma Cmax,ss lev-596
els less than 0.346 ng/ml have worse outcomes than597
those with levels above this threshold at the 8 mg/day 598
dose. At substantially higher plasma concentrations, 599
in the range 6.8–14.2 ng/ml seen in patients receiv- 600
ing the 200 mg/day dose, treatment effects are also 601
generally worse. 602
In order to inform a future confirmatory study, 603
binary outcome analyses were performed in which 604
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Fig. 4. Model-derived least square mean and standard error estimates of change of 52 weeks for clinical (a, b, c, d) and MRI volumetric
endpoints (e, f) in patients taking hydromethylthionine 8 mg/day categorized by plasma levels above or below the Cmax,ss threshold of
0.346 ng/ml.
the group of patients with minimal systemic expo-605
sure to the drug was used as a proxy for placebo.606
These are shown in Table 6 and illustrated in Fig. 4.607
Compared to patients with subthreshold plasma608
concentrations, patients with plasma Cmax,ss above609
the 0.346 ng/ml threshold at the 8 mg/day dose have610
significantly better outcomes on FAQ, Modified-611
CGIC, WBV, LVV, and FTV, and near-significant612
differences on ACE-R and UPDRS. There are no613
exposure-dependent differences in MMSE or FRS.614
Treatment differences are generally larger for com-615
parisons restricted to patients receiving the 8 mg/day616
dose. This is due to inclusion of patients receiving617
the 200 mg/day dose who have worse outcomes than618
patients with above-threshold plasma levels at the619
8 mg/day dose.620
In order to understand the exposure-response rela- 621
tionship better, the data were explored further using 622
an expanded version of the Hill equation [60]. This 623
provided a robust fit to the mean concentration- 624
response for change in ACE-R, FAQ, and WBV over 625
52 weeks (Fig. 5). The model fit for these outcomes is 626
consistent with the assumption that the lower limiting 627
plasma concentration required for treatment response 628
is 0.29 ng/ml in patients receiving the 8 mg/day dose. 629
The whole brain volume data in patients receiving the 630
200 mg/day dose were sufficiently homogeneous to 631
permit further subgrouping into terciles (Fig. 5). This 632
made it possible to derive an estimate of the upper 633
limiting concentration (13.6 ng/ml, corresponding to 634
a theoretical dose of 301 mg/day) at which the treat- 635
ment effect would be lost (Fig. 5). 636
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Table 7
Number (%) of patients with at least one TEAE with an incidence of ≥5% of patients in any treatment group – Safety Population
MedDRA System Organ Hydromethylthionine Hydromethylthionine
Class/Preferred Term 8 mg/day (n = 110) 200 mg/day (n = 108)
Patients Reporting at Least One Adverse Event 88 (80.0%) 103 (95.4%)
Gastrointestinal disorders 28 (25.5%) 42 (38.9%)
Diarrhea 9 (8.2%) 24 (22.2%)
Vomiting 5 (4.5%) 9 (8.3%)
Infections and infestations 38 (34.5%) 34 (31.5%)
Nasopharyngitis 8 (7.3%) 7 (6.5%)
Urinary tract infection 13 (11.8%) 14 (13.0%)
Injury, poisoning and procedural complications 18 (16.4%) 16 (14.8%)
Fall 10 (9.1%) 13 (12.0%)
Investigations 17 (15.5%) 34 (31.5%)
Blood folate decreased 6 (5.5%) 9 (8.3%)
White blood cells urine positive 1 (0.9%) 6 (5.6%)
Metabolism and nutrition disorders 12 (10.9%) 14 (13.0%)
Folate deficiency 2 (1.8%) 6 (5.6%)
Nervous system disorders 33 (30.5%) 27 (25.0%)
Headache 8 (7.3%) 5 (4.6%)
Psychiatric disorders 29 (26.4%) 31 (28.7%)
Agitation 9 (8.2%) 9 (8.3%)
Insomnia 3 (2.7%) 7 (6.5%)
Renal and urinary disorders 25 (22.7%) 28 (25.9%)
Dysuria 0 6 (5.6%)
Pollakiuria 3 (2.7%) 10 (9.3%)
Urinary incontinence 13 (11.8%) 9 (8.3%)
Respiratory, thoracic and mediastinal disorders 12 (10.9%) 8 (7.4%)
Cough 7 (6.4%) 2 (1.9%)
Using data from the combined AD and bvFTD637
populations, we have reported previously that a dose638
of 16 mg/day would be sufficient to ensure that639
all patients have plasma levels above the threshold640
required for pharmacological activity [47]. However,641
the Hill equation analyses suggests that pharmaco-642
logical activity is predicted to peak in the vicinity of643
a 30 mg/day dose (Fig. 5). At this dose, the treat-644
ment effect on the FAQ scale is predicted to be645
7.73 [CI 5.50, 12.81] units (mean and confidence646
interval based on bootstrap analysis), and the treat-647
ment effect on whole brain atrophy is predicted to648
be 18.52 cm3 [CI 14.29 cm3, 23.70 cm3]. A simula-649
tion of the plasma concentration profile for 30 mg/day650
given as single daily dose is shown in the Supplemen-651
tary Figure 1.652
Safety outcomes653
The safety evaluation was based on the 218 patients654
who enrolled in this study and took at least one dose of655
hydromethylthionine (Safety Population). Of the 218656
patients in the Safety Population, 110 (50.5%) were657
randomized to 8 mg/day and 108 (49.5%) were ran-658
domized to 200 mg/day. The compliance was high,659
97% for 8 mg/day and 94% for 200 mg/day patients660
meeting a criterion defined as between 80% and661
120% of planned doses based on tablet returns. The 662
8 mg/day dose was better tolerated, with a withdrawal 663
rate of 15% over 12 months compared with 38% for 664
the 200 mg/day dose. 665
Treatment emergent adverse events (TEAEs) were 666
reported by 88 (80%) patients in the 8 mg/day group 667
and 103 (95.4%) patients in the 200 mg/day group. 668
TEAEs were judged by the Investigator to be related 669
to study drug in 30% of patients in the 8 mg/day group 670
and 56% of patients taking 200 mg/day. The major- 671
ity of TEAEs were mild to moderate in intensity. 672
A summary of TEAEs with an incidence of ≥5% 673
of patients in any treatment group is provided in 674
Table 6. TEAEs that showed an increase in incidence 675
with hydromethylthionine 200 mg/day relative to 676
8 mg/day include anemia, diarrhea, dysuria, nausea, 677
pollakiuria, insomnia, and vomiting. Renal and uri- 678
nary disorders were reported with greater frequency 679
in patients receiving hydromethylthionine 8 mg/day 680
with above-threshold plasma levels (26%) compared 681
with those with below-threshold levels (18%). At 682
least one severe TEAE was reported in 13 (12%) 683
hydromethylthionine 8 mg/day patients and 17 (16%) 684
in 200 mg/day patients. More patients (35 [32%]) 685
treated with hydromethylthionine 200 mg/day expe- 686
rienced a TEAE resulting in a dose reduction, 687
interruption, or withdrawal of study drug as com- 688
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Fig. 5. Expanded Hill equation analysis of pharmacological activ-
ity of hydromethylthionine on change in ACE-R, FAQ, and WBV
52 weeks using model-derived least squares mean and standard
error estimates of change over 65 weeks for clinical (a,b) and MRI
volumetric (c) endpoints according to plasma concentration group
(8 mg/day) or dose (200 mg/day). Scales at the top of each panel
indicate actual doses or calculated theoretical intermediate doses.
pared to patients treated with hydromethylthionine689
8 mg/day (15 [14%]). The UPDRS was included to690
ensure there was no adverse effect on motor func-691
tion. Patients did not have evidence of impaired motor692
function at the start of treatment and there was no693
worsening over time.694
Protocol-specified adverse events of special inter- 695
est included significant hematological findings 696
(methemoglobinemia, hemolytic anemia, presence 697
of Heinz bodies), serotonin syndrome, and ARIA. 698
The frequency of affirmative C-SSRS responses prior 699
to treatment was the same for both dosage groups 700
(8 mg/day, 7 (6.4%); 200 mg/day, 6 (5.6%)) and 701
remained unchanged following treatment. There was 702
one aborted suicide attempt in a patient who had 703
a prior history of an attempt that was not reported 704
as a TEAE and the patient continued with treat- 705
ment. There was 1 death among patients receiving 706
hydromethylthionine at the 8 mg/day dose, and 3 in 707
patients exposed to the 200 mg/day dose. None of 708
these events was judged by the investigator as being 709
related to treatment. Patients were closely monitored 710
for evidence of possible serotonin syndrome/toxicity 711
using a 20-item structured examination based on 712
published criteria [62, 63]. No subject had sero- 713
tonin syndrome reported as an AE. Three subjects 714
(2 randomized to 8 mg/day and 1 randomized to 715
200 mg/day) had myoclonus reported as an AE. How- 716
ever, none of these was considered by investigators 717
to be due to serotonin toxicity after clinical review. 718
DISCUSSION 719
We report the results of the largest therapeutic trial 720
conducted in bvFTD to date along with an embed- 721
ded population PK analysis. The study was designed 722
to compare a high dose of hydromethylthionine 723
(200 mg/day) with a low dose (8 mg/day) intended 724
as a control. As in two similarly designed trials in 725
AD [42, 43], there were no significant differences 726
between these two doses on any efficacy outcome. 727
In AD, we have reported recently that there are 728
steep concentration-response relationships on cogni- 729
tive and MRI outcomes for steady state plasma levels 730
in the range 0.3–0.8 ng/ml at the 8 mg/day dose, and 731
that plasma concentrations in the range 4–21 ng/ml 732
produced by doses in the range 150–250 mg/day are 733
not associated with any additional benefit [47]. We 734
now report a similar exposure-response profile in 735
bvFTD. There are steep concentration-response rela- 736
tionships on clinical and MRI outcomes for steady 737
state plasma levels in the range 0.3–0.6 ng/ml on the 738
clinical ACE-R and FAQ scales and whole brain atro- 739
phy measured by MRI. High plasma concentrations 740
in the range 7–14 ng/ml produced by the 200 mg/day 741
dose produce worse outcomes. 742
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The exposure-response space we have now been743
able to define permits a better understanding of744
the relationship between dose and pharmacologi-745
cal activity. The lack of dose-response comparing746
hydromethylthionine at 8 mg/day with 200 mg/day747
is due to two main factors. First, there is a steep748
exposure-response relationship at the 8 mg/day dose749
such that the majority of patients have blood levels750
sufficient for pharmacological activity on clinical and751
MRI volumetric outcomes. Second, there is a bipha-752
sic response at concentrations substantially higher753
than required for pharmacological activity such the754
pharmacological activity at 200 mg/day is either no755
greater or less compared with that seen in patients756
with adequate blood levels at the 8 mg/day dose.757
Modelling using an expanded version of the Hill758
equation produced robust fits to the clinical and759
MRI data. This analysis suggests that 0.29 ng/ml is760
the minimum limiting plasma concentration of the761
drug required for pharmacological activity, and that762
13.6 ng/ml (corresponding to a theoretical dose of763
301 mg/day) is the upper limiting concentration for764
activity.765
We have reported recently that variability in expo-766
sure at the 8 mg/day dose is determined primarily767
by renal function as measured by creatinine clear-768
ance [47]. Patients with high creatinine clearance769
have relatively lower steady state plasma levels of the770
drug and vice versa. Since the bvFTD population is771
younger and the mean creatinine clearance is higher, a772
higher dose of hydromethylthionine may be required773
than in AD. Whereas the predicted optimal dose for774
treatment of AD is about 16 mg/day, we estimate that775
a dose in the vicinity of 30 mg/day is required in776
bvFTD. The Hill equation analysis suggests that a777
broad range of doses (20–60 mg/day) are likely to778
produce roughly comparable treatment effects and779
would provide an adequate range for dosing flexi-780
bility in clinical practice.781
The doses of hydromethylthionine required for782
pharmacological activity are substantially lower than783
that previously identified for MTC in AD [45].784
Hydromethylthionine has better brain delivery of785
LMT than does MTC following oral dosing [30,786
47]. This is due in part to 20-fold more efficient787
uptake into red blood cells which is needed for788
the drug to escape first-pass metabolism which789
leads to loss of activity [25], and a correspond-790
ing 60-fold better brain:plasma ratio compared to791
MTC [47]. The plasma concentration threshold of792
0.346 ng/ml required for clinical pharmacological793
activity in bvFTD is very close to that identified in794
mild/moderate AD (Cmax,ss 0.373 ng/ml). Likewise, 795
the non-linear concentration-response profile is sim- 796
ilar to that seen in AD [47], although the biphasic 797
response profile is somewhat more pronounced in 798
bvFTD. Both diseases are characterized by pathol- 799
ogy of protein aggregation. The protein involved is 800
TDP-43 in more than half of bvFTD cases, whereas 801
in AD it is tau protein in the majority of cases, with 802
an unknown contribution of cases with limbic TDP- 803
43 pathology [64]. The estimated brain concentration 804
of hydromethylthionine required for pharmacologi- 805
cal activity (0.02–0.09M) [47] is consistent with 806
its activity as an inhibitor of both tau [26] and TDP- 807
43 aggregation [65] in vitro, and with the doses 808
required for activity in a tau transgenic mouse model 809
of bvFTD [30]. In addition to different clinical man- 810
ifestations and response to symptomatic treatments, 811
the underlying pathology affects different classes of 812
brain cells with a different neuroanatomical distribu- 813
tion in AD and bvFTD [66–68]. It is therefore striking 814
that hydromethylthionine has similar pharmacologi- 815
cal activity with respect to clinical decline and brain 816
atrophy over similar concentration ranges of the drug 817
in two distinct neurodegenerative disorders. 818
In addition to effects on pathological protein aggre- 819
gation, the MT moiety has been reported to have 820
effects on dopamine and serotonin. Bhurtel and col- 821
leagues reported that MTC (given in the oxidized 822
MT+ form as MTC at a dose of 20 mg/kg intraperi- 823
toneally) restores dopamine levels in a mouse model 824
of Parkinson’s disease using 1-methyl-4-phenyl- 825
1,2,3,6-tetrahydropyridine (MPTP) [69]. MPTP is 826
not itself toxic, but produces toxicity in dopaminer- 827
gic neurons via a metabolite produced by monoamine 828
oxidase in the brain [70]. However, no effect was 829
seen when MTC was given alone, suggesting that 830
the primary mechanism is via an interaction with 831
monoamine oxidase. It has been reported that MT+ 832
inhibits monoamine oxidase (IC50 5.5M; [71]) and 833
serotonin transporter (IC50 1.2M; [72]) activity in 834
vitro. Since the estimated brain concentrations of 835
hydromethylthionine required for clinical pharma- 836
cological activity in bvFTD are more than an order 837
of magnitude below these values it is unlikely that 838
the treatment effects seen clinically are mediated 839
by a direct effect on serotonin neurotransmission. 840
Using a tau transgenic mouse model, we have recently 841
reported that hydromethylthionine increases acetyl- 842
choline levels in the hippocampus and normalizes 843
glutamate release in synaptosomes prepared from 844
brain tissues at clinically relevant doses. It is there- 845
fore likely that, in addition to effects on protein 846
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aggregation pathology, there are secondary effects847
in neurotransmitter systems compromised by pathol-848
ogy.849
We have used the results from this study to inform850
the design of a planned placebo-controlled trial. For851
this purpose, we defined a subthreshold patient group852
with minimal drug exposure as a proxy for placebo.853
The study was powered to detect a 50% reduction854
in the expected annual decline over 52 weeks for855
patients with definite evidence of fronto-temporal856
atrophy estimated to be 13.4 ± 2.1 ACE-R units based857
on an observational study [49]. The decline observed858
in patients with minimal drug exposure as defined by859
the 0.346 ng/ml threshold is 11.3 ± 2.1 ACE-R units,860
and is therefore comparable, although a more recent861
study in patients meeting only clinical diagnostic cri-862
teria reported a smaller decline [4]. Other than the863
Kipps et al. study [49], which included MRI evidence864
of fronto-temporal atrophy to exclude phenocopies,865
other available studies had only clinical requirements866
using either the Neary et al. [73] or Rascovsky et867
al. [1] criteria. In the comparisons which follow, we868
have used the published data to calculate standard869
errors for comparison. The annualized decline on870
the FAQ scale was reported as 5.81 ± 1.11 units in871
bvFTD [20], 5.6 to 8.8 units (extrapolated from 26-872
week data in patients randomized to either placebo or873
memantine [17]), and 3.73 ± 0.39 [74]. The decline874
observed in patients with subthreshold plasma lev-875
els was 7.13 ± 1.06 units. The ADCS-CGIC score876
after 12 months was reported as 5.27 (SD 0.88)877
[20], corresponding to a change score of –1.27 ± 1.11878
units. The decline on the Modified-CGIC in patients879
with subthreshold plasma levels was –1.34 ± 0.20880
units. The annualized decline on the MMSE scale has881
been reported as –2.45 ± 0.79 [20] and –3.98 ± 0.54882
[74]. The MMSE decline observed in patients with883
subthreshold plasma levels was –2.95 ± 0.93 units.884
Finally, the decline in whole brain volume reported in885
a bvFTD cohort was 20.8 cm3 [75]. The correspond-886
ing decline in patients with subthreshold plasma887
levels was 27.7 ± 2.7 cm3. Therefore, allowing for888
differences in patient selection criteria, the decline889
observed across multiple metrics in patients with min-890
imal drug exposure is comparable to that reported891
for patients in historical studies. Compared against892
patients with subthreshold plasma levels, the treat-893
ment differences for patients receiving 8 mg/day with894
plasma levels above the 0.346 ng/ml threshold are895
5.1 units (p = 0.0536, 45% reduction) on the ACE-R896
scale, –3.3 units (p = 0.0131, 46% reduction) on the897
FAQ scale, 0.64 Modified-CGIC units (p = 0.0157,898
48% reduction), –4.3 UPDRS units (p = 0.0711, 75% 899
reduction) and 11.7 cm3 (p = 0.0006, 42% reduction) 900
in whole brain atrophy. These binary exposure- 901
dependent differences cannot be accounted for by 902
differences in severity, sex, age, co-medication status 903
with AD drugs, or geography since these variables are 904
corrected for in the concentration-response analysis 905
model. 906
There have been several proposals regarding selec- 907
tion of primary and secondary outcomes for studies in 908
bvFTD, based on historical observational data, the- 909
oretical treatment effect sizes and other theoretical 910
considerations [20, 74–77]. Unlike AD, where trial 911
methodology has evolved over a 40-year period and 912
a consensus has emerged as to which domains which 913
should be assessed as primary outcomes, there is no 914
general agreement as to the best ways to measure 915
treatment effects in bvFTD. In a recent review, 50 916
different primary and secondary outcome scales are 917
listed for clinical trials reported in bvFTD between 918
2003-2015 [77]. Based on the present results, FAQ 919
and Modified-CGIC appear to have the greatest 920
power as clinical outcomes in practice, consistent 921
with previous suggestions [74, 75], and change in 922
whole brain [75] or lateral ventricular volume have 923
the greatest power as supportive biomarker outcomes. 924
In contrast to AD, the functional outcome measure 925
(FAQ) performs better than the cognitive outcome 926
measures (ACE-R and ACE-III) we have used. It also 927
has greater clinical relevance and face validity [51]. 928
An apparent effect on the UPDRS motor assessment 929
scale is surprising, although involvement of basal 930
regions early in the disease process has been reported 931
[78, 79]. 932
The safety profile of hydromethylthionine seen in 933
the present study is very similar to that seen in the two 934
AD studies we have reported. Comparing 200 mg/day 935
with 8 mg/day, there is a dose-dependent increase in 936
adverse events recorded as anemia, dysuria, pollak- 937
iuria, diarrhea, nausea, insomnia, and vomiting. In 938
patients receiving the 8 mg/day dose, the higher fre- 939
quency of renal and urinary adverse events in patients 940
with above- versus below-threshold plasma levels 941
(26% versus 18%) is consistent with higher plasma 942
levels. At a dose of 8 mg/day, the safety profile is 943
generally benign. This dose is well tolerated, with a 944
withdrawal rate of 15% over 12 months, compared 945
with 38% for the 200 mg/day dose. 946
There are important limitations in the inferences 947
which can be drawn from the present study. A post- 948
hoc exposure-response analysis of the kind we have 949
undertaken does not prove efficacy. It provides a 950
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means of determining how pharmacological activ-951
ity is related to plasma concentration, and hence952
dose. However, pharmacological activity is not the953
same thing as efficacy. Efficacy can be established954
only by demonstrating a statistically significant effect955
on prespecified outcomes in a suitable randomized956
placebo-controlled trial. The analyses presented here957
are hypothesis generating and serve the purpose of958
informing the design of a confirmatory placebo-959
controlled trial which is now planned. The group960
sizes in the analyses comparing exposure-dependent961
differences at the 8 mg/day dose are small (46–62962
with high exposure against 28–31 with low exposure),963
although comparable with other studies conducted in964
bvFTD [13–18]. The fact that there are consistent965
exposure-dependent differences achieving nominal966
significance on a range of clinical and MRI outcomes967
based on relatively small numbers of subjects sug-968
gests that the effects, if confirmed, are likely to be969
clinically meaningful.970
Conclusion971
We report the results of the largest clinical trial972
in bvFTD to have been conducted to date, combined973
with a population PK analysis in 80% of the par-974
ticipating patients in whom drug concentration and975
efficacy outcome data were available. The random-976
ized comparisons between hydromethylthionine at977
a dose of 200 mg/day and a low dose of 8 mg/day,978
thought to be inactive, did not show any difference979
on the intended primary or secondary outcomes.980
However, the population PK analyses conducted981
post-hoc imply that 8 mg/day produces significantly982
better outcomes in patients with adequate exposure983
to the drug compared to those with minimal expo-984
sure at the same dose. Hydromethylthionine shows a985
biphasic concentration-response profile such that the986
high plasma levels associated with the 200 mg/day987
dose produce worse outcomes. In patients with988
adequate systemic exposure at the 8 mg/day dose,989
hydromethylthione has pharmacological activity with990
respect to clinical decline and brain atrophy, reducing991
decline by almost half compared with patients with992
minimal drug exposure. If confirmed in a further trial,993
these would represent potentially meaningful clinical994
gains in a severely debilitating condition for which no995
effective treatment options exist at present. The sim-996
ilarity in the concentration-response profiles at the997
8 mg/day dose in AD and bvFTD is consistent with998
a common molecular mechanism of action linked999
to inhibition of pathological protein aggregation. A1000
placebo-controlled trial in bvFTD aiming to deter- 1001
mine whether hydromethylthionine is efficacious in 1002
bvFTD is now planned. 1003
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